Company intelligence
Sobi - Swedish Orphan Biovitrum AB (publ)
About Sobi - Swedish Orphan Biovitrum AB (publ)
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. We are dedicated to capturing the scientific opportunities of our time. With our early roots in Sweden, we started as pioneers in haemophilia. Today we are an innovative leader within rare diseases with a global reach. Together we are bringing brilliant ideas to life. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Verified activity
Signals from Sobi - Swedish Orphan Biovitrum AB (publ)
2 published signals
Customers & Market
Sobi - Swedish Orphan Biovitrum AB (publ) treated over 53,000 patients with a Sobi medicine in 2025.
Reported by Sobi - Swedish Orphan Biovitrum AB (publ)
People
Sobi - Swedish Orphan Biovitrum AB (publ) announced the first promotion of graduates at LEO Pharma.
Reported by Christophe Bourdon